Colossal's $20-30B Mega-Round Talks, Happy Health's $75M Austin Sleep-Tech Raise, and CPRIT's Platform Overhaul Mark a Quieter, Institution-Building August for Texas Health Tech.
September 2026 | Vol. 1, Issue 5
Mapping the intersection of medicine and venture capital across the Texas Triangle.
Executive Summary
After July's fireworks, Function Health's $450 million non-dilutive raise, Forte Biosciences' $2.2 billion sale to Agenx, and the Hill County litigation finale, August settled into a quieter rhythm. Texas CEO Magazine's own weekly deal desk called it plainly mid-month: a short list, a quiet week. But quiet doesn't mean uneventful. The month's real headline isn't a closed deal at all, it's Dallas-based Colossal Biosciences reportedly in talks to raise new capital at a $20 billion to $30 billion valuation, roughly double to triple where the de-extinction giant sat just sixteen months ago, a story that was still developing as this issue went to press.
On the financing side, Austin's Happy Health closed a $75 million Series A to scale its FDA-cleared smart ring and home-based sleep-care platform, while a much smaller but telling signal came from INNOVOTEX, an Austin oncology-therapeutics startup that raised a $4 million seed round to advance texaphyrin-based treatments for platinum-resistant tumors; a reminder that Austin's early stage biotech pipeline is still filling in behind the mega-rounds. On the institutional side, CPRIT delivered on the timeline it flagged last issue, opening the first module of its new Grant Management Platform in August as promised, while its de-extinction neighbor's nonprofit arm, the Colossal Foundation, opened its second annual cohort of conservation grants.
Macro Signals
Colossal Biosciences in talks to raise at a $20B-$30B valuation
Dallas-based Colossal Biosciences, the de-extinction company behind the dire wolf revival and the woolly mammoth and dodo bird projects, is reportedly in talks to raise new capital at a valuation of $20 billion to $30 billion, according to Axios reporting relayed by TechCrunch in late July. That would mark a two-to-three-times step-up from the roughly $10.2 billion valuation the company held about sixteen months earlier. It isn't yet clear who is leading the prospective round or how much the five-year-old company is looking to raise, and as of this writing the deal has not closed.
The Signal: Whether or not the round closes at the reported range, the story underscores how far Colossal has pushed beyond its original de-extinction pitch. The company says it has begun generating revenue over the past year and has spun out three separate ventures from its core science: Form Bio (computational biology), Breaking (plastics degradation) and Astromech, an AI-driven predictive-modeling company for biology and life sciences that itself reached a $2 billion valuation in March. For Dallas-area investors, Colossal has become the closest thing North Texas has to a venture-backed decacorn flywheel, spinning off independently fundable companies from a single R&D platform rather than a single product. A raise anywhere near the reported range would make it one of the largest private financings in Texas history, health-tech or otherwise, and would be worth revisiting once terms are confirmed.
Happy Health's $75 million Series A for home-based sleep care
Austin-based Happy Health secured $75 million in Series A funding led by ARCH Venture Partners and OpenLoop to continue building its AI-powered platform for continuous, home-based care. The company's first application is sleep: its clinical-grade Happy Ring, which first received FDA clearance in October 2024, was later cleared for at-home sleep testing in June 2025, making it the first FDA-cleared smart ring approved for multi-night sleep testing and continuous biometrics. Happy Sleep, the company's sleep-medicine platform, pairs the ring with a clinical care team of board-certified sleep physicians and says it is in-network with most major health plans, including Blue Cross and Medicare.
The Signal: Happy Health's raise adds another Austin name to a growing list of consumer hardware-plus-clinical-service plays that lean on a wearable to unlock a reimbursable care pathway rather than selling the device alone — the same basic architecture Function Health has built around lab testing and imaging. ARCH Venture Partners' participation is notable given the firm's much larger recent bets in AI-driven biotech and diagnostics; its move into a consumer wearable-plus-telehealth model suggests investors see continuous physiological monitoring as a wedge into broader home-care markets, not just a sleep-tracking niche.
CPRIT's Grant Management Platform launches on schedule
As flagged in last issue, the Cancer Prevention and Research Institute of Texas opened the first module of its new Grant Management Platform in August, on the timeline the agency announced back in July. The module supports the FY27.2 Academic Research and Prevention grant application cycles; CPRIT says the post-award management and peer-review modules will follow in January 2027, at which point the agency's legacy CARS, P2RMIS and CGMS systems will be retired.
The Signal: This is process infrastructure, not funding news, but it matters to anyone building a CPRIT application pipeline. The new platform consolidates what has been a fragmented, multi-system workflow into a single portal, and CPRIT has been explicit that legacy systems go dark once the January 2027 modules ship. Texas life-sciences founders and grant administrators with cycles spanning that transition should budget time to re-familiarize teams with the new system rather than assuming a like-for-like migration.
Colossal Foundation opens second annual conservation grant cohort
The Colossal Foundation, the nonprofit conservation arm of Colossal Biosciences, announced on August 5 that it is opening its second annual cohort of catalytic grants, genetic technologies and technical support for species-recovery projects, selected from more than $5 million in funding requests.
The Signal: It's a nonprofit program rather than a venture deal, but it's a useful marker of how Colossal is converting its core genomic-engineering platform into a broader ecosystem play grants, spinouts, and now a second full grant cycle well ahead of any resolution of its reported mega-round talks.
May Deal Tracker
| Company | Hub | Stage | Deal Value | Lead / Notable News |
|---|---|---|---|---|
| Colossal Biosciences | Dallas | Growth (in talks) | $20.0B-$30.0B (reported valuation) | Reportedly in talks for new financing per Axios/TechCrunch; round not yet closed or confirmed |
| Happy Health | Austin | Series A | $75.0M | ARCH Venture Partners & OpenLoop co-lead; funds FDA-cleared Happy Ring and home-based sleep-care platform |
| INNOVOTEX | Austin | Seed | $4.0M | Keiretsu Forum leads; advances texaphyrin-based oncology therapeutics for platinum-resistant solid tumors |
| CPRIT Grant Management Platform | Statewide | Regulatory | N/A | First GMP module launched in August as scheduled, supporting FY27.2 grant cycles |
| Colossal Foundation Grant Cohort | Dallas | Institutional / Philanthropic | $5.0M+ (requested) | Second annual conservation-grant cohort opened August 5 |
Seed & Early Stage Rounds
INNOVOTEX (Austin) – Seed, $4 million
The Austin-based developer of texaphyrin-based oncology therapeutics closed a $4 million seed round led by Keiretsu Forum, bringing its total raised to $4.83 million. The company is targeting platinum-resistant solid tumors, an indication where existing chemotherapy options frequently fail. It's a small round by the standards of this report's usual deal size, but a useful counterpoint to the mega-rounds dominating headlines: Austin's earliest-stage biotech pipeline continues to draw capital even in a summer otherwise dominated by consumer health and de-extinction headlines.
Series A Rounds
Happy Health (Austin) – $75 million Series A
Happy Health's raise, led by ARCH Venture Partners and OpenLoop, funds continued build-out of its AI-powered continuous home-care platform, anchored by the FDA-cleared Happy Ring. The device's October 2024 clearance and June 2025 at-home sleep-testing clearance make it the first FDA-cleared smart ring approved for multi-night sleep studies and round-the-clock biometrics. The company's Happy Sleep platform pairs the hardware with a board-certified sleep-physician care team and in-network status with major payers, including Blue Cross and Medicare.
Growth / Late-Stage Rounds
(In Motion) Colossal Biosciences (Dallas) – Reported $20B-$30B Valuation Talks
Colossal is reportedly in discussions for a new financing round at a valuation of $20 billion to $30 billion, a two-to-three-times step-up from its roughly $10.2 billion valuation set about sixteen months earlier, according to Axios reporting relayed by TechCrunch on July 20. The lead investor and round size have not been disclosed, and the round had not closed as of this writing. Colossal says it has started generating revenue over the past year and has spun off three ventures to date. Form Bio, Breaking, and the $2 billion-valued Astromech.
Exits & M&A
No Texas-based health-tech or biotech exit of note closed in August. Following July's $2.2 billion Forte Biosciences sale to Agenx, the largest healthcare exit out of North Texas so far in 2026, the state's deal desk described August's overall flow as notably quieter, consistent with the broader late-summer lull typical of the sector.
Regulatory & Institutional Notes
CPRIT's new Grant Management Platform goes live
PRIT opened the first module of its new Grant Management Platform in August, on schedule with the timeline announced in July. The module supports the FY27.2 Academic Research and Prevention grant application cycles. Post-award management and peer-review modules follow in January 2027, at which point the agency's legacy CARS, P2RMIS and CGMS systems retire for good. CPRIT has published a "How to Apply" instructional video and user guide for organizations preparing for the transition.
Colossal Foundation's second grant cohort
Separately from any financing talks at the parent company, the Colossal Foundation opened its second annual cohort of conservation grants on August 5, selecting recipients from more than $5 million in funding requests for species-recovery and biodiversity work, continuing a program that pairs catalytic grants with Colossal's genetic-technology and biobanking infrastructure.
Upcoming Events
Texas Health Informatics Alliance (THIA) Sixth Annual Conference
When / Where: September 18, 2026 | UT Arlington / DFW Regional Hub
Information: Co-hosted by a coalition of Texas medical schools including UTHealth Houston, UTSW, and UNT, the theme is "From Innovation to Impact: Implementing Trustworthy Health Informatics Across Texas." A hotspot for VCs evaluating B2B hospital infrastructure, clinical AI governance, and digital twins.
2026 iC³ Life Science & Healthcare Innovation Summit
When / Where: September 24–25, 2026 | Loews Arlington Hotel & Convention Center
Information: Hosted by BioNTX, North Texas's premier annual life sciences summit, a major networking hub for institutional lifetech VCs and pharma business development execs.
The 2026 Healthcare Innovation Summit – Houston
When / Where: October 15, 2026 | Intercontinental Houston
Information: A targeted buyer-and-seller summit connecting C-level healthcare executives with the enterprise healthtech startup ecosystem.
MedCity INVEST Digital Health 2026
When / Where: October 29, 2026 | Pegasus Park (Dallas)
Information: One of the premier nationwide digital health investment conferences, held at the heart of Texas's core biotech park, with heavy participation from national corporate venture capital funds.
Sources
Temkin, Marina. "Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation." TechCrunch, 20 July 2026, techcrunch.com/2026/07/20/colossal-biosciences-reportedly-in-talks-to-raise-new-capital-at-20b-30b-valuation/.
Dallas Innovates / Colossal Biosciences newsroom. "The Colossal Foundation Opens Second Annual Cohort of Conservation Grants." PR Newswire, 5 Aug. 2026.
"This animal is next species Dallas' Colossal plans to bring back from extinction." The Dallas Morning News, 2026, www.dallasnews.com/business/technology/article/colossal-biosciences-announces-next-animal-plans-22230083.php.
"Happy Health secures $75M for AI-driven home-based care platform." Fierce Healthcare, 18 Aug. 2026, www.fiercehealthcare.com/finance/happy-health-secures-75m-ai-driven-home-based-care-platform.
Fierce Healthcare Fundraising Tracker '26. Fierce Healthcare, updated 27 Aug. 2026, www.fiercehealthcare.com/health-tech/fierce-healthcare-fundraising-tracker-26.
"MaxQ Medical Raises $31.5 Million Series A, Backed by Olympus, to Advance its Prostate Care Platform." PR Newswire, 20 Aug. 2026, www.prnewswire.com/news-releases/maxq-medical-raises-31-5-million-series-a-backed-by-olympus-to-advance-its-prostate-care-platform-302855815.html.
Texas CEO Magazine, Joel Trammell, and Mason Rathe. "Texas Weekly Deal Highlights." Texas CEO Magazine, 9 Aug. 2026, www.texasceomagazine.com/p/texas-weekly-deal-highlights-03a.
Texas CEO Magazine, Joel Trammell, and Mason Rathe. "Texas Weekly Deal Highlights." Texas CEO Magazine, 16 Aug. 2026, www.texasceomagazine.com/p/texas-weekly-deal-highlights-6d2.
Cancer Prevention and Research Institute of Texas. "CPRIT to launch a new Grant Management Platform in August." CPRIT News & Events, 8 July 2026, www.cprit.texas.gov/news-events/articles/cprit-to-launch-a-new-grant-management-platform-in-august/.
Cancer Prevention and Research Institute of Texas. "What is the CPRIT Grant Management Platform (GMP)?" cprit.texas.gov, 2026, cprit.texas.gov/about-us/new-grant-management-platform/.
Disclaimer: The Givens Health Venture Report is for informational purposes only and does not constitute financial, legal, or investment advice. The views, data, and analysis expressed in this report are entirely independent and not affiliated with, endorsed by, or representative of any of the venture capital firms, corporate entities, state agencies, or healthcare institutions mentioned herein. Past performance or deal trajectory is not indicative of future market results.
